Perioperative pregabalin does not reduce opioid requirements in total knee arthroplasty

87 patients with osteoarthritis and scheduled for total knee arthroplasty (TKA) were randomized to receive oral peri-operative pregabalin or placebo for the reduction of opioid consumption and pain following surgery. The primary outcome of interest was cumulative morphine consumption during the first 72 hours post-operation. Secondary outcomes of interest included pain on a Visual Analog Scale (VAS), range of motion, Knee Society Score (KSS) function and knee scores, the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index, and the Short-Form 26 (SF-36) Mental and Physical Component Scales (MCS; PCS). Patient-reported outcome measures were reported up to 6 months post-operation. Results revealed no significant differences in all outcomes between the pregabalin and control groups.